Liver Histology in a ‘Normal’ Population—Examinations of 503 Consecutive Fatal Traffic Casualties

Hilden, Malene; Christoffersen, Per; Juhl, E; Dalgaard, Jørgen B.

doi:10.3109/00365527709181339

Cited by 231 publications

(128 citation statements)

References 3 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of hepatic steatosis in the asymptomatic general population is not well documented in the published literature, with varying results from 3.5% to 24%, as described below (13)(14)(15)(16)(17). Two postmortem studies of random deaths have reported on the prevalence of hepatic steatosis: in a study of 423 aircrew involved in fatal aircraft accidents, 66 cases (15%) had a fatty liver, 11 of which had histopathological evidence of alcohol abuse (14); in a study of 503 fatal road traffic accidents, 24% had a fatty liver and fatty change was significantly correlated with body weight and increasing age (13).…”

Section: Discussionmentioning

confidence: 96%

“…Two postmortem studies of random deaths have reported on the prevalence of hepatic steatosis: in a study of 423 aircrew involved in fatal aircraft accidents, 66 cases (15%) had a fatty liver, 11 of which had histopathological evidence of alcohol abuse (14); in a study of 503 fatal road traffic accidents, 24% had a fatty liver and fatty change was significantly correlated with body weight and increasing age (13). In neither of these studies was detailed information concerning alcohol misuse available.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography

et al. 2003

View full text Add to dashboard Cite

Objective: Hepatic steatosis may occur in association with insulin resistance and obesity, two features commonly seen in Cushing's syndrome (CS). The aim of this report is to assess the prevalence of hepatic steatosis in patients with active CS using computed tomography (CT) and to identify any associations between hepatic steatosis, endocrine and biochemical variables and body fat distribution. Patients and measurements: We identified 50 patients with active CS in whom appropriate CT was available to allow measurement of liver and spleen attenuation. In 26 patients, abdominal fat measurements were also available. Serum markers of CS and liver function tests were recorded. Results: Ten of 50 patients had a liver-to-spleen CT attenuation ratio (L/S) of less than 1, indicating hepatic steatosis. There was a significant negative correlation between both liver attenuation and L/S ratio with total abdominal fat area, visceral fat area, the percentage of visceral fat and the visceral to subcutaneous fat ratio; the strongest negative correlation was found between visceral fat area and L/S ratio (r ¼ 2 0.638, P , 0.001, n ¼ 26). L/S ratio positively correlated with alkaline phosphatase levels (r ¼ þ0.423, P ¼ 0.044, n ¼ 23) but with no other serum marker of CS activity or liver enzyme. Conclusions: We have demonstrated hepatic steatosis on CT in 20% of patients with active CS. The presence of hepatic steatosis was significantly correlated with total abdominal fat area and visceral fat area.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography

et al. 2003

View full text Add to dashboard Cite

show abstract

“…1,2 In random histopathologic studies, the relative proportion of NASH to NAFLD is approximately 1:10. 36,37 This problem has never been systematically evaluated, and selection biases might operate differently in the various series. In the present study, liver biopsy was limited to a subgroup of patients, and it is possible that more severe cases were preferentially selected or gave informed consent to biopsy.…”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

et al. 2003

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin-resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. We assessed the prevalence of the metabolic syndrome in 304 consecutive NAFLD patients without overt diabetes, on the basis of 3 or more criteria out of 5 defined by the U.S. National Institutes of Health (waist circumference, glucose, high-density lipoprotein [HDL]-cholesterol, triglycerides, and arterial pressure). The prevalence of the metabolic syndrome increased with increasing body mass index, from 18% in normal-weight subjects to 67% in obesity. Insulin resistance (Homeostasis Model Assessment method) was significantly associated with the metabolic syndrome (odds ratio [OR], 2.5; 95% CI, 1.5-4.2; P < .001). Liver biopsy was available in 163 cases (54%). A total of 120 patients (73.6%) were classified as having nonalcoholic steatohepatitis (NASH); 88% of them had a metabolic syndrome (vs. 53% of patients with pure fatty liver; P < .0001). Logistic regression analysis confirmed that the presence of metabolic syndrome carried a high risk of NASH among NAFLD subjects (OR, 3.2; 95% CI, 1.2-8.9; P ‫؍‬ .026) after correction for sex, age, and body mass. In particular, the syndrome was associated with a high risk of severe fibrosis (OR, 3.5; 95% CI, 1.1-11.2; P ‫؍‬ .032). In conclusion, the presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease. The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades. (HEPATOLOGY 2003;37:917-923.)

show abstract

“…NAFLD is perhaps the most common of all liver disorders. [17][18][19][20][21][22][23] Wanless and Lentz 24 found steatosis in 70% of obese and 35% of lean patients and NASH in 18.5% of obese and 2.7% of lean patients in a consecutive autopsy study. Among obese patients, the prevalence of class 1 NAFLD (simple steatosis) is about 60%, whereas NASH is found in 20% to 25% and 2% to 3% have cirrhosis.…”

Section: Clinical Aspectsmentioning

confidence: 99%